Prelude Therapeutics Inc

Listed Company

PRLDCIK 0001678660NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$12.14M

Net Income

$-99.50M

Total Assets

$141.31M

Equity

$68.64M

Shares Out

63.00M

Op. Cash Flow

$-56.30M

Business

Prelude Therapeutics Inc is a clinical-stage precision oncology company that discovers and develops novel small molecules, targeted protein degraders and precision antibody drug conjugates for underserved cancer patients. It offers internally discovered new chemical entities and biologic collaborations, progressing product candidates such as SMARCA2 degraders (PRT3789, PRT7732), a CDK9 inhibitor (PRT2527), and precision ADC payloads through preclinical and clinical development. Its operations include discovery, preclinical research, clinical development and partnerships (e.g., AbCellera, Merck) as key functional divisions. The company conducts global clinical trials, relies on third-party manufacturers and distributors, and pursues commercialization through internal or collaborative channels worldwide.

Summary from filing dated 2025-03-10

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	12	7	—	—	—
Research and development	94	118	103	93	87
General and administrative	22	29	29	31	27
Total operating expenses	117	147	132	124	114
Loss from operations	−105	−140	−132	−124	−114
Other income, net	5	13	10	8	2
Net loss	−99	−127	−122	−115	−112
Net loss per share of common stock, basic	−1.29	−1.68	−2.02	−2.44	−2.43
Net loss per share of common stock, diluted	−1.29	−1.68	−2.02	−2.44	−2.43
Weighted average common shares outstanding, basic	77	76	60	47	46
Weighted average common shares outstanding diluted	77	76	60	47	46
Unrealized (loss) on marketable securities, net of tax	−27,000	−188,000	2	−981,000	−711,000
Comprehensive loss	−100	−127	−120	−116	−112

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	35	12	25	31	32
Marketable securities	68	121	208	171	259
Prepaid expenses and other current assets	2	2	3	3	4
Total current assets	106	136	236	204	295
Restricted cash	3	4	4	4	4
Property and equipment, net	5	7	7	5	4
Right-of-use asset	27	29	30	2	2
Prepaid expenses and other non-current assets	110,000	110,000	295,000	5	—
Total assets	141	176	278	221	305
Accounts payable	4	8	5	7	8
Accrued expenses and other current liabilities	13	15	16	13	10
Deferred revenue	34	0	—	—	—
Operating lease liability	3	2	1	2	2
Finance lease liability	0	208,000	—	—	—
Total current liabilities	53	26	22	22	19
Deferred revenue, net of current portion	2	0	—	—	—
Other liabilities	3	3	3	3	0
Operating lease liability	15	15	15	—	—
Total liabilities	73	44	41	25	19
Commitments (note 8)	—	—	—	—	—
Additional paid-in capital	752	715	693	532	506
Accumulated other comprehensive income	8,000	35,000	223,000	−2	−711,000
Accumulated deficit	−683	−584	−456	−335	−219
Total stockholders equity	69	131	237	195	286
Total liabilities and stockholders equity	141	176	278	221	305

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−99	−127	−122	−115	−112
Depreciation and amortization	2	2	1	1	915,000
Noncash lease expense	2	2	2	2	1
Stock-based compensation	12	21	26	25	21
Amortization of premium and discount on marketable securities, net	−371,000	−5	−3	3	1
Prepaid expenses and other current assets	−197,000	373,000	−297,000	−4	−1
Accounts payable	−4	3	−2	−347,000	4
Accrued expenses and other liabilities	−3	−808,000	3	7	2
Deferred revenue	36	0	—	—	—
Long-term prepaid expenses and other long-term assets	0	295,000	−9	—	—
Operating lease liabilities	−28,000	1	−2	−2	−1
Net cash used in operating activities	−56	−103	−107	−84	−84
Purchases of marketable securities	−101	−53	−222	−119	−261
Proceeds from maturities of marketable securities	154	144	191	204	—
Purchases of property and equipment	−67,000	−764,000	−4	−3	−2
Net cash provided by investing activities	53	90	−35	82	−264
Proceeds from issuance of common stock in connection with the Securities Purchase Agreement	25	0	—	—	—
Payment of offering costs	0	−110,000	—	—	−303,000
Proceeds from issuance of common stock in connection with the exercise of stock options	16,000	60,000	47,000	389,000	4
Proceeds from the issuance of common stock under ESPP	150,000	379,000	634,000	426,000	272,000
Payment of withholding taxes related to stock-based compensation to employees	−17,000	−54,000	−17,000	—	—
Principal payments on finance lease	−208,000	−395,000	—	—	—
Net cash provided by (used in) financing activities	25	−120,000	136	815,000	165
Net increase (decrease) in cash and cash equivalents	22	−13	−5	−1	−182
Property and equipment in accounts payable	0	10,000	163,000	90,000	806,000
Unrealized loss on marketable securities	−27,000	−188,000	2	−981,000	−711,000
Offering costs in accounts payable and accrued expenses and other current liabilities	234,000	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro